正大企业国际2023年年报

Stock Code3839( Incorporated in Bermuda with members’ limited liability於百慕達註冊成立之成員有限責任公司 )股份代號 : 目錄CONTENTS Chairman’s Statement董事長報告書Financial Highlights財務概要Management Discussion and Analysis管理層討論及分析Corporate Governance Report企業管治報告Biographical Details of Directors董事履歷詳情Report of The Directors董事報告書Independent Auditor’s Report獨立核數師報告Consolidated Statement of Comprehensive Income綜合全面收益表Consolidated Statement of Financial Position綜合財務狀況表Consolidated Statement of Changes in Equity綜合權益變動表Consolidated Statement of Cash Flows綜合現金流量表Notes to the Financial Statements財務報表附註Corporate Information公司資料245103641606769717375151 Chairman’s Statement董 事 長 報 告 書 5.2% In 2023, with most of the major economies slowing down in growth,“high inflation, high interest rate and meagre growth” were the mosttalked about traits of the global economic environment. In China,despite showing tremendous resilience and development potential,her economy was under pressure from demand contracting, supplyside disruptions and weakening expectation. As the global supplychain went through restructuring, China’s leadership in the globalsupply chain was also challenged. The Chinese economy generallyslowed down with gross domestic product growth at 5.2% for the year.Despite being affected by multiple unfavourable factors at home andabroad, Chia Tai Enterprises International Limited (the “Company”)and its subsidiaries (the “Group”) – by formulating effective businessstrategies, firmly upholding corporate values and striving for progresson an even keel – were still able to take business forward. Onthe biochemical business front,with society emphasisingmore- a n d - m o r eo n h i g h - q u a l i t y d e v e l o p m e n t ,t h e C h i n e s egovernment has continued to tighten livestock product qualityand safety, as well as environmental protection requirements ofthe farming industry. Regulatory bodies have been adjusting andimproving policies relevant to the animal pharmaceutical industry,with the aim of strengthening monitoring and raising the quality andsafety standard of animal pharmaceutical products. Such moves havespurred animal pharmaceutical companies to enhance cost controland increase investment in research and development. The Groupcontinued during the year to hire and train high-calibre talent anddirect resources into upgrading product technologies so as to bolsterits core competitiveness. Atthe same time,the Group has pressed on with strategictransformation to build up its animal health business, working towardsbecoming a leading bio-technology company. In 2023, animal healthbusiness achieved a major milestone, with revenue exceeding half ofthat of the Group’s biochemical business for the first time. The Groupwill actively explore new opportunities in this promising businessarena. Chairman’s Statement董 事 長 報 告 書 In2023,the Group,as always,actively honoured its socialresponsibility by participating in an array of social welfare andcharitable events: caring for the underprivileged, supporting educationof poor students, sponsoring medical supplies, promoting greening,etc. In the aspect of human resources, during the year, the Grouprecruited a group of talent with high qualifications to undertakeresearch and development, as well as production and sales tasks,allowing it to further improve manpower structure and staff quality.Moreover, the Group also kept strengthening management of internalprocedures, as well as clarifying roles and responsibilities, in a bidto improve efficiency and shore up strength in order to give a solidfoundation for the Group to achieve sustainable development. ECI MetroInvestment Co., Ltd. Despite the challenging macro-economic environment, our ECI MetroInvestment Co., Ltd. benefited from demand for Caterpillar’s newelectric-driven loader models. These products, which meet China’stightened low carbon standards, were much welcomed by the market.On the other hand, we are closely monitoring development of theelectric vehicle market in China, as we guide our investee ZhanjiangDeni Vehicles Parts Company Limited. Looking ahead, the Group expects the teetering economic recoveryand intensifying competition to bring uncertainties to its businesses.Thus, we maintain an overall cautious view of our performance in2024. Nevertheless, we will grasp opportunities in the market as itprogresses to normalcy, and continue to uphold our “Three BenefitsPrinciple” – benefiting the countries in which we operate, benefitingthe people whose community we share and benefiting the enterprisesfor which we are responsible. We will abide by environmental lawsand regulations, tackle uncertainties in the operating environmentandwork hard on meeting the requirements of high-qualitydevelopment, so as to ensure we are ready to realise our businessdevelopment aspirations in 2024. Last but not least, my heartfelt thanks go to all employees for theirhard work and contribution and also to shareholders for their trustand support. Soopakij Chear